Showing 1,098 results

Filters Content type: News, Editors' picks, About HIV Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Hepatitis C treatment

Updated Hepatitis C Practice Guidelines Now Available from AASLD

Editor's pick
Market Watch (press release)
28 September 2011
Hepatitis C treatment side-effects

Coffee consumption reduces side-effects in people on hepatitis C treatment

News
14 September 2011
New & experimental hepatitis C treatment

Treatment Action Group publishes Guide to Clinical Trials for People With Hepatitis C

Editor's pick
Treatment Action Group
17 August 2011
Adherence

Injection Drug Users and Adherence to Hepatitis C Treatment

Editor's pick
HIV & Hepatitis
1 August 2011
Hepatitis C treatment

Boceprevir response and resistance differs according to HCV genotype 1 subtype

News
28 July 2011
Hepatitis C treatment

Maraviroc improves liver fibrosis in HIV/hepatitis C co-infected patients

News
20 July 2011
Hepatitis C transmission & prevention

Hepatitis Scotland launched to tackle viral hepatitis

Editor's pick
Scottish Drugs Forum
29 June 2011
Hepatitis C treatment

With special training, effective and safe hepatitis C therapy can be provided in primary care

News
23 June 2011
Hepatitis C treatment

Coffee drinking improves hepatitis C treatment response rate in mono-infected patients

News
22 June 2011
Hepatitis C treatment

HIV-positive patients who receive therapy for acute HCV can be cured with just 24 weeks of therapy

News
6 June 2011
New & experimental hepatitis C treatment

Why Incivek and Victrelis Herald a New Era in Hepatitis C Treatment

Editor's pick
The Body
3 June 2011
Hepatitis C treatment

The Fair Pricing Coalition Expresses Disappointment at the Price of Vertex’s Newly Approved Hepatitis C Drug

Editor's pick
Fair Pricing Coalition
25 May 2011
New & experimental hepatitis C treatment

US approval for hepatitis C drug telaprevir

News
23 May 2011
New & experimental hepatitis C treatment

European approval recommended for hepatitis C drug boceprevir

News
23 May 2011
New & experimental hepatitis C treatment

Merck, Roche to Work Together on Hepatitis C Treatments

Editor's pick
San Francisco Chronicle
18 May 2011
New & experimental hepatitis C treatment

Getting Ready; Telaprevir or Boceprevir ?

Editor's pick
HCV New Drugs Research
18 May 2011
New & experimental hepatitis C treatment

Merck’s Hepatitis C Drug Wins F.D.A. Approval

Editor's pick
New York Times
16 May 2011
Hepatitis C symptoms & diagnosis

Age-Based Hep C Screening May Work Better Than Risk-Based Screening

Editor's pick
Internal Medicine News
9 May 2011
Hepatitis C treatment

Genetic variation associated with response to hepatitis C therapy in HIV co-infected patients

News
5 May 2011
Hepatitis C treatment

HIV treatment preserves CD4 cell count during and after HCV therapy in co-infected patients

News
3 May 2011
New & experimental hepatitis C treatment

Vertex hepatitis C drug gets glowing endorsement

Editor's pick
Reuters
29 April 2011
Hepatitis C treatment

Twice-weekly pegylated interferon improved early treatment responses in co-infected patients

News
28 April 2011
New & experimental hepatitis C treatment

US FDA panel backs Merck hepatitis drug

Editor's pick
Reuters
28 April 2011
New & experimental hepatitis C treatment

European Gastroenterologists Will Prescribe Telaprevir and Boceprevir to Nonresponder and Treatment-Naive Patients Following Launch, Leading to Higher Treatment Costs Than Interviewed Payers Expect

Editor's pick
Business Wire
19 April 2011